01—Abstract
Summary
Summary of the 8-K filed August 4, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories reported second quarter 2026 results on August 4, 2026, with revenue of $1,217 milliona, up 10% as reported and 9% organic.
Growth was led by Companion Animal Group (CAG) at 9%b and CAG Diagnostics recurring revenue, which rose 11% as reported and 10% organic, with International up 12% organic and U.S. up 10%. Management attributed the strength to volume-driven utilization, net customer expansion, and the growing premium instrument installed base, now 11% larger. Water grew 15% as reported and 13% organic, and LPD grew 11% as reported and 9% organic.
Profitability improved meaningfully. Gross margin rose 140 basis points to 64.0%, and operating margin rose 140 basis points to 35.0% as reported (110 basis points comparable). Diluted EPS was $4.27c, up 18% as reported and 15% comparable.
Note that EPS included $0.14d of share-based compensation tax benefits and $0.06 of currency benefit, so comparable EPS of $4.07 is the cleaner run-rate measure. Operating expenses grew 10%, reflecting investments in commercial capabilities, innovation, and IT. Full-year 2026 guidance was modestly raised.
Revenue is now expected at $4,700 million to $4,745 million, a $5 million increase at the midpoint after a $15 million FX headwind. EPS guidance rose to $14.69 to $14.94 from $14.45 to $14.90 at the prior midpoint, though a meaningful portion of the increase reflects share-based compensation benefits rather than operations. Management also reported strong cash generation, with six-month free cash flow of $557 million, and continued share repurchases of about $693 million in the open market during the first half.
02—Key points
Key Highlights
- Revenue of $1,217 million grew 10% as reported and 9% organic, with CAG Diagnostics recurring revenue up 11% as reported and 10% organic.
- Gross margin expanded 140 bps to 64.0% and operating margin expanded 140 bps to 35.0% as reported (110 bps comparable), despite operating expenses rising 10%.
- Diluted EPS of $4.27 rose 18% as reported and 15% comparable; comparable EPS of $4.07 excludes $0.14 of share-based comp tax benefits and $0.06 of currency gains.
- The IDEXX inVue Dx installed base surpassed 9,000 instruments after over 1,600 placements in the quarter, while capital instrument revenue fell 19% against a tough prior-year comparison.
- 2026 revenue guidance narrowed to $4,700M–$4,745M (9.1%–10.3% reported growth), with the midpoint raised $5M net of a $15M FX headwind.
- 2026 EPS guidance raised to $14.69–$14.94, with the increase driven partly by $0.05 of higher share-based compensation benefits rather than operations alone.
- Six-month free cash flow of $557 million (up from $360 million) and $693 million of open-market buybacks at an average cost of $592 per share underscore capital return capacity; a 2026 Investor Day is scheduled for August 13.
03—Questions
Frequently Asked Questions
How strong was the underlying organic growth, and what drove it?
Organic revenue grew 9% in the quarter, with CAG Diagnostics recurring revenue up 10% organically. Management credited volume-driven utilization, net new customer gains, benefits from IDEXX innovations such as Catalyst and Fecal Dx, and growth in the premium instrument installed base. VetLab consumables grew 14% organically, while rapid assay products were roughly flat at 1%.
Is the margin expansion sustainable, or was it flattered by one-time items?
The operating margin gain was largely operational: gross margin benefited from recurring revenue volume, productivity, and net pricing. Comparable operating margin still rose 110 bps. The prior-year period included a roughly $9 million litigation accrual reduction that inflated the 2025 comparison slightly, and this year's EPS included $0.14 of share-based compensation tax benefits that are not operational and may vary by period.
Why did EPS guidance rise by more than the operating outlook alone would suggest?
Of the $0.14 midpoint EPS increase, about $0.14 came from operational performance, $0.05 from higher share-based compensation tax benefits, and a $0.05 headwind from updated FX estimates. Investors should note that the share-based compensation component is discrete and not a recurring operating driver.
What are the key risks to the outlook?
Risks include FX movements (a stronger U.S. dollar already reduced 2026 revenue by $15M and about 0.6 points of growth), a slowdown in U.S. clinical visits or pet population trends, competitive or pricing pressure, and the timing of instrument placements, as capital revenue fell 19% this quarter. Management also flagged geopolitical, tariff, and supply chain risks in its forward-looking statements.
04—Continue